These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27736846)

  • 1. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
    Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
    Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL
    Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
    Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
    Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
    Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
    Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
    Hertz DL; Roy S; Jack J; Motsinger-Reif AA; Drobish A; Clark LS; Carey LA; Dees EC; McLeod HL
    Breast Cancer Res Treat; 2014 May; 145(1):245-54. PubMed ID: 24706167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
    Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
    Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
    J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.
    Hertz DL; Roy S; Motsinger-Reif AA; Drobish A; Clark LS; McLeod HL; Carey LA; Dees EC
    Ann Oncol; 2013 Jun; 24(6):1472-8. PubMed ID: 23413280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
    Apellániz-Ruiz M; Lee MY; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; García-Estévez L; Sereno M; García-Donás J; Castelo B; Guerra E; Leandro-García LJ; Cascón A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodríguez-Antona C
    Clin Cancer Res; 2015 Jan; 21(2):322-8. PubMed ID: 25398452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Sequencing Reveals Low-Frequency Variants in
    Apellániz-Ruiz M; Tejero H; Inglada-Pérez L; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; Castelo B; Redondo A; García-Donás J; Romero-Laorden N; Sereno M; Merino M; Currás-Freixes M; Montero-Conde C; Mancikova V; Åvall-Lundqvist E; Green H; Al-Shahrour F; Cascón A; Robledo M; Rodríguez-Antona C
    Clin Cancer Res; 2017 Mar; 23(5):1227-1235. PubMed ID: 27582484
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
    Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
    Fukada I; Ito Y; Kobayashi K; Shibayama T; Takahashi S; Horii R; Akiyama F; Iwase T; Ohno S
    PLoS One; 2017; 12(9):e0184322. PubMed ID: 28898275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
    Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
    Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
    Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
    Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
    Leandro-García LJ; Leskelä S; Jara C; Gréen H; Avall-Lundqvist E; Wheeler HE; Dolan ME; Inglada-Perez L; Maliszewska A; de Cubas AA; Comino-Méndez I; Mancikova V; Cascón A; Robledo M; Rodríguez-Antona C
    Clin Cancer Res; 2012 Aug; 18(16):4441-8. PubMed ID: 22718863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
    Shen F; Jiang G; Philips S; Gardner L; Xue G; Cantor E; Ly RC; Osei W; Wu X; Dang C; Northfelt D; Skaar T; Miller KD; Sledge GW; Schneider BP
    Clin Cancer Res; 2023 Jul; 29(13):2494-2500. PubMed ID: 37126018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
    Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
    Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
    Chang H; Rha SY; Jeung HC; Im CK; Ahn JB; Kwon WS; Yoo NC; Roh JK; Chung HC
    Ann Oncol; 2009 Feb; 20(2):272-7. PubMed ID: 18836089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
    Chhibber A; Mefford J; Stahl EA; Pendergrass SA; Baldwin RM; Owzar K; Li M; Winer EP; Hudis CA; Zembutsu H; Kubo M; Nakamura Y; McLeod HL; Ratain MJ; Shulman LN; Ritchie MD; Plenge RM; Witte JS; Kroetz DL
    Pharmacogenomics J; 2014 Aug; 14(4):336-42. PubMed ID: 24513692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.